Cost-effectiveness of routine adolescent vaccination with an M72/AS01_E-like tuberculosis vaccine in South Africa and India.

ABSTRACT: The M72/AS01_E tuberculosis vaccine showed 50% (95%CI: 2-74%) efficacy in a phase 2B trial in preventing active pulmonary tuberculosis disease, but potential cost-effectiveness of adolescent immunisation is unknown. We estimated the impact and cost-effectiveness of six scenarios of routine adolescent M72/AS01_E-like vaccination in South Africa and India. All scenarios suggested an M72/AS01_E-like vaccine would be highly (94-100%) cost-effective in South Africa compared to a cost-effectiveness threshold of $2480/disability-adjusted life-year (DALY) averted. For India, a prevention of disease vaccine, effective irrespective of recipient's M. tuberculosis infection status at time of administration, was also highly likely (92-100%) cost-effective at a threshold of

SUBMITTER: Harris RC 

PROVIDER: S-EPMC8807591 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature